Chemoprevention of primary liver cancer: a randomized, double-blind trial in Linxian, China
- PMID: 17686823
- DOI: 10.1093/jnci/djm084
Chemoprevention of primary liver cancer: a randomized, double-blind trial in Linxian, China
Abstract
Background: Primary liver cancer is a common malignancy with a dismal prognosis. New primary prevention strategies are needed to reduce mortality from this disease. We examined the effects of supplementation with four different combinations of vitamins and minerals on primary liver cancer mortality among 29450 initially healthy adults from Linxian, China.
Methods: Participants were randomly assigned to take either a vitamin-mineral combination ("factor") or a placebo daily for 5.25 years (March 1986-May 1991). Four factors (at doses one to two times the US Recommended Daily Allowance)-retinol and zinc (factor A); riboflavin and niacin (factor B); ascorbic acid and molybdenum (factor C); and beta-carotene, alpha-tocopherol, and selenium (factor D)-were tested in a partial factorial design. The study outcome was primary liver cancer death occurring from 1986 through 2001. Adjusted Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of liver cancer death with and without each factor. All P values are two-sided.
Results: A total of 151 liver cancer deaths occurred during the analysis period. No statistically significant differences in liver cancer mortality were found comparing the presence and absence of any of the four intervention factors. However, both factor A and factor B reduced liver cancer mortality in individuals younger than 55 years at randomization (HR = 0.59, 95% CI = 0.34 to 1.00, and HR = 0.54, 95% CI = 0.31 to 0.93, respectively) but not in older individuals (HR = 1.06, 95% CI = 0.71 to 1.59, and HR = 1.12, 95% CI = 0.75 to 1.68, respectively). Factor C reduced liver cancer death, albeit with only borderline statistical significance in males (HR = 0.70, 95% CI = 0.47 to 1.02) but not in females (HR = 1.30, 95% CI = 0.72 to 2.37). Cumulative risks of liver cancer death were 6.0 per 1000 in the placebo arm, 5.4 per 1000 in the arms with two factors, and 2.4 per 1000 in the arm with all four factors.
Conclusion: None of the factors tested reduced overall liver cancer mortality. However, three factors reduced liver cancer mortality in certain subgroups.
Similar articles
-
Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China.Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1562-4. doi: 10.1158/1055-9965.EPI-06-0316. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16896051 Clinical Trial.
-
Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population.J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92. doi: 10.1093/jnci/85.18.1483. J Natl Cancer Inst. 1993. PMID: 8360931 Clinical Trial.
-
Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group.Cancer Res. 1994 Apr 1;54(7 Suppl):2029s-2031s. Cancer Res. 1994. PMID: 8137333 Clinical Trial.
-
Vitamin/mineral supplementation and cancer risk: international chemoprevention trials.Proc Soc Exp Biol Med. 1997 Nov;216(2):291-6. doi: 10.3181/00379727-216-44180. Proc Soc Exp Biol Med. 1997. PMID: 9349699 Review.
-
Micronutrient supplementation trials and the reduction of cancer and cerebrovascular incidence and mortality.Nutr Rev. 1994 Mar;52(3):102-5. doi: 10.1111/j.1753-4887.1994.tb01399.x. Nutr Rev. 1994. PMID: 8015747 Review.
Cited by
-
Association of serum α-tocopherol, β-carotene, and retinol with liver cancer incidence and chronic liver disease mortality.Br J Cancer. 2014 Nov 25;111(11):2163-71. doi: 10.1038/bjc.2014.365. Epub 2014 Oct 14. Br J Cancer. 2014. PMID: 25314058 Free PMC article.
-
Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial.J Natl Cancer Inst. 2009 Apr 1;101(7):507-18. doi: 10.1093/jnci/djp037. Epub 2009 Mar 24. J Natl Cancer Inst. 2009. PMID: 19318634 Free PMC article. Clinical Trial.
-
Antioxidant supplements for preventing gastrointestinal cancers.Cochrane Database Syst Rev. 2008 Jul 16;2008(3):CD004183. doi: 10.1002/14651858.CD004183.pub3. Cochrane Database Syst Rev. 2008. PMID: 18677777 Free PMC article.
-
Fumonisin B1 and risk of hepatocellular carcinoma in two Chinese cohorts.Food Chem Toxicol. 2012 Mar;50(3-4):679-83. doi: 10.1016/j.fct.2011.11.029. Epub 2011 Nov 29. Food Chem Toxicol. 2012. PMID: 22142693 Free PMC article.
-
Role of nicotinamide in DNA damage, mutagenesis, and DNA repair.J Nucleic Acids. 2010 Jul 25;2010:157591. doi: 10.4061/2010/157591. J Nucleic Acids. 2010. PMID: 20725615 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical